Don't miss this! #ADCs are a rapidly advancing class of #biotherapeutics that combine the targeting capability of monoclonal antibodies with the cytotoxic potential of small-molecule drugs. In our upcoming #elearning opportunity, experts explore a series of case studies highlighting the critical bioanalytical testing and CMC characterization approaches necessary to support ADC development. BioAgilytix panelists include Sarah Crittenden, Timothy Myers, Ph.D., Gregory Reynolds, and Bryan Thacker, Ph.D.
